Markus Ritzefeld

Markus Ritzefeld

Auto-generated profile, based on publicly available information

Markus Ritzefeld

Department of Chemistry Imperial College London London W12 0BZ UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2014 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
MRMarkus Ritzefeld
Markus Ritzefeld

28 February 2012 in Journal of Amino Acids
Verified
Journal Article
Open access
PDF file
MRMarkus Ritzefeld
Markus Ritzefeld
NSNorbert Sewald
Norbert Sewald
Several proteins, like transcription factors, bind to certain DNA sequences, thereby regulating biochemical pathways that determine the fate of the corresponding cell. Due to these key positions, it is indispensable to analyze protein-DNA interactions and to identify their mode of action. Surface plasmon resonance is a label-free method that facilitates the elucidation of real-time kinetics of biomolecular interactions. In this article, we focus on this biosensor-based method and provide a detailed guide how SPR can be utilized to study binding of proteins to oligonucleotides. After a description of the physical phenomenon and the instrumental realization including fiber-optic-based SPR and SPR imaging, we will continue with a survey of immobilization methods. Subsequently, we will focus on the optimization of the experiment, expose pitfalls, and introduce how data should be analyzed and published. Finally, we summarize several interesting publications of the last decades dealing with protein-DNA and RNA interaction analysis by SPR.

8 March 2017 in Parasitology
Verified
Journal Article
Closed access
PDF file
MRMarkus Ritzefeld
Markus Ritzefeld
MWMegan H. Wright
Megan H. Wright
ETEdward W. Tate
Edward W. Tate
SUMMARY: Infections by protozoan parasites, such asPlasmodium falciparumorLeishmania donovani, have a significant health, social and economic impact and threaten billions of people living in tropical and sub-tropical regions of developing countries worldwide. The increasing range of parasite strains resistant to frontline therapeutics makes the identification of novel drug targets and the development of corresponding inhibitors vital. Post-translational modifications (PTMs) are important modulators of biology and inhibition of protein lipidation has emerged as a promising therapeutic strategy for treatment of parasitic diseases. In this review we summarize the latest insights into protein lipidation in protozoan parasites. We discuss how recent chemical proteomic approaches have delivered the first global overviews of protein lipidation in these organisms, contributing to our understanding of the role of this PTM in critical metabolic and cellular functions. Additionally, we highlight the development of new small molecule inhibitors to target parasite acyl transferases.

1 July 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
TLThomas Lanyon-Hogg
Thomas Lanyon-Hogg
MRMarkus Ritzefeld
Markus Ritzefeld
LSLea Sefer
Lea Sefer
JBJasmine K. Bickel
Jasmine K. Bickel
ARAmalie F. Rudolf
Amalie F. Rudolf
ETEdward W. Tate
Edward W. Tate
Posttranslational attachment of lipids to proteins is important for many cellular functions, and the enzymes responsible for these modifications are implicated in many diseases, from cancer to neurodegeneration. Lipid transferases and hydrolases are increasingly tractable therapeutic targets, but present unique challenges for high-throughput biochemical enzyme assays which hinder development of new inhibitors. We present Acylation-coupled Lipophilic Induction of Polarisation (Acyl-cLIP) as the first universally applicable biochemical lipidation assay, exploiting the hydrophobic nature of lipidated peptides to drive a polarised fluorescence readout. Acyl-cLIP allows sensitive, accurate, real-time measurement of S- or N-palmitoylation, N-myristoylation, S-farnesylation or S-geranylgeranylation. Furthermore, it is applicable to transfer and hydrolysis reactions, and we demonstrate its extension to a high-throughput screening format. We anticipate that Acyl-cLIP will greatly expedite future drug discovery efforts against these challenging targets.

7 March 2013 in Amino Acids
Verified
Journal Article
Closed access
PDF file
MRMarkus Ritzefeld
Markus Ritzefeld
VWVolker Walhorn
Volker Walhorn
DADario Anselmetti
Dario Anselmetti
NSNorbert Sewald
Norbert Sewald

24 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ABAndrew S. Bell
Andrew S. Bell
ZYZhiyong Yu
Zhiyong Yu
JHJennie A. Hutton
Jennie A. Hutton
MWMegan H. Wright
Megan H. Wright
JBJames A. Brannigan
James A. Brannigan
ETEdward W. Tate
Edward W. Tate
The leishmaniases, caused by Leishmania species of protozoan parasites, are neglected tropical diseases with millions of cases worldwide. Current therapeutic approaches are limited by toxicity, resistance, and cost. N-Myristoyltransferase (NMT), an enzyme ubiquitous and essential in all eukaryotes, has been validated via genetic and pharmacological methods as a promising anti-leishmanial target. Here we describe a comprehensive structure–activity relationship (SAR) study of a thienopyrimidine series previously identified in a high-throughput screen against Leishmania NMT, across 68 compounds in enzyme- and cell-based assay formats. Using a chemical tagging target engagement biomarker assay, we identify the first inhibitor in this series with on-target NMT activity in leishmania parasites. Furthermore, crystal structure analyses of 12 derivatives in complex with Leishmania major NMT revealed key factors important for future structure-guided optimization delivering IMP-105 (43), a compound with modest activity against Leishmania donovani intracellular amastigotes and excellent selectivity (>660-fold) for Leishmania NMT over human NMTs.